Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,920
Total Claims
$2.4M
Drug Cost
597
Beneficiaries
$4,094
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+173%
Opioid rate vs peers
6.1% vs 2.2% avg
+190%
Cost per patient vs peers
$4,094 vs $1,411 avg
+53%
Brand preference vs peers
16.3% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
6.1%
Opioid Rate
667
Opioid Claims
$25K
Opioid Cost
6.3%
Long-Acting Rate
Brand vs Generic
Brand: 1,769 claims · $2.2M
Generic: 9,089 claims · $236K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 199 | $304K |
| Semaglutide | 106 | $224K |
| Empagliflozin | 119 | $192K |
| Dulaglutide | 74 | $151K |
| Semaglutide | 63 | $149K |
| Tirzepatide | 53 | $116K |
| Evolocumab | 74 | $109K |
| Apixaban | 70 | $93K |
| Rivaroxaban | 49 | $78K |
| Insulin Degludec | 49 | $64K |
| Linaclotide | 36 | $45K |
| Lipase/Protease/Amylase | 16 | $35K |
| Insulin Glargine,hum.Rec.Anlog | 49 | $33K |
| Vibegron | 30 | $31K |
| Denosumab | 18 | $31K |
Prescribing Profile
Patient Profile
72
Avg Age
54%
Female
1.61
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About